Nanogam (intravenous normal human immunoglobulin)
/ Sanquin
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 25, 2024
Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients
(clinicaltrials.gov)
- P4 | N=178 | Completed | Sponsor: Konya City Hospital
New P4 trial • Critical care • Infectious Disease • Novel Coronavirus Disease
April 20, 2021
An infusion of antibodies to COVID-19 for patients with B cell disorder, a randomized (randomized) study (COVID Compromise study).
(clinicaltrialsregister.eu)
- P3; N=86; Ongoing; Sponsor: Amsterdam UMC
Clinical • New P3 trial • Infectious Disease • Multiple Myeloma • Novel Coronavirus Disease • Respiratory Diseases • CD20
April 07, 2021
Borrelia burgdorferi sensu lato seroconversion after intravenous immunoglobulin treatment: a cohort study.
(PubMed, Eur J Neurol)
- "Transient presence of anti-Bbsl IgG antibodies after IVIg is regularly observed. This effect appears to be dependent on the IVIg brand, probably reflecting variation in Bbsl exposure of plasma donors. Lyme borreliosis serological testing during, and weeks to months after IVIg, is therefore of limited utility."
Journal • Immunology • Inflammatory Arthritis • Lyme Disease • Myositis • Pain
March 31, 2021
The ConvP COVig PKPD study: an investigation for the use of plasma or antibodies against the novel coronavirus (SARS-CoV-2) De ConvP COVig PKPD studie: een onderzoek naar nuttig gebruik van plasma of antilichamen voor behandeling van het nieuwe coronavirus (SARS-CoV-2)
(clinicaltrialsregister.eu)
- P1/2; N=104; Ongoing; Sponsor: Erasmus MC
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1